Research Topics
Species | Laurence KlotzSummaryAffiliation: Sunnybrook Health Sciences Centre Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?Laurence Klotz
Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
Semin Radiat Oncol 18:2-6. 2008..The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed...
What is the best approach for screen-detected low volume cancers?--The case for observationLaurence Klotz
Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Urol Oncol 26:495-9. 2008....- Combined androgen blockade: an updateLaurence Klotz
Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada
Urol Clin North Am 33:161-6, v-vi. 2006..This treatment must be balanced against the potential for an increase in side-effects and a consequent adverse effect on the patient's quality of life... - Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapyNicholas Bruchovsky
The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
Cancer 109:858-67. 2007..Biochemical results from a prospective Phase II trial of intermittent androgen suppression for recurrent prostate cancer after radiotherapy were analyzed for correlations to the onset of hormone-refractory disease... - Active surveillance: patient selectionLaurence Klotz
Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Curr Opin Urol 23:239-44. 2013..This is a summary of the current approach to patient selection for active surveillance, including eligibility criteria, current controversies and the role of imaging... - A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprLaurence H Klotz
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
Eur Urol 63:927-35. 2013..We sought to determine whether a weekly dose of alendronate, an oral bisphosphonate, could reduce this unwanted side-effect... - Active surveillance for prostate cancer: overview and updateLaurence Klotz
Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave MG 408, Toronto, M4N 3M5, Ontario, Canada
Curr Treat Options Oncol 14:97-108. 2013..Active surveillance is increasingly viewed as the management of choice for patients with very low-risk (low-grade, low-volume prostate cancer) and low-risk (low-grade but higher volume) disease... - Cancer overdiagnosis and overtreatmentLaurence Klotz
Division of Urology, University of Toronto, Toranto, Ontario, Canada
Curr Opin Urol 22:203-9. 2012..Overdiagnosis has become a major problem in medicine in general and cancer in particular. This is a summary of this problem... 
Active surveillance: the Canadian experience with an "inclusive approach"Laurence Klotz
Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, 2075 Bayview Ave, Toronto, Ontario
J Natl Cancer Inst Monogr 2012:234-41. 2012..Further studies are warranted to improve the identification of patients who harbor more aggressive disease in spite of favorable clinical parameters at diagnosis [reproduced from Klotz (1) with permission from Wolters Kluwer Health]...- Active surveillance: the Canadian experienceLaurence Klotz
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Curr Opin Urol 22:222-30. 2012..This article is a summary of the rationale, method, and results of active surveillance beginning in 1995 with the first prospective trial of this approach... - Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomesLaurence Klotz
Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue MG408, Toronto, ON, M4N 3M5, Canada
Curr Urol Rep 13:153-9. 2012..This review article summarizes the evidence supporting active surveillance, and the current approach to this management strategy, including the roles of serial biopsy, PSA kinetics, and MR imaging... - Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4David Cervi
1Department of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
BMC Cancer 10:258. 2010..The purpose herein was to discover, validate and characterize functional biomarkers of dietary supplementation capable of suppressing the course of prostate cancer in vivo... - Point: active surveillance for favorable risk prostate cancerLaurence Klotz
University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue MG408, Toronto, Ontario, Canada
J Natl Compr Canc Netw 5:693-8. 2007..This article reviews the results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention... - Active surveillance for prostate cancer: trials and tribulationsLaurence Klotz
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, MG 408, Toronto, ON, M4N 3M5, Canada
World J Urol 26:437-42. 2008.... - Maximal androgen blockade for advanced prostate cancerLaurence Klotz
Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, ON, Canada
Best Pract Res Clin Endocrinol Metab 22:331-40. 2008..In prostate cancer patients at high risk for mortality (based on extent of disease or prostate-specific antigen kinetics), combination therapy with bicalutamide should be considered in preference to monotherapy... - Active surveillance for favorable risk prostate cancer: rationale, risks, and resultsLaurence Klotz
University of Toronto Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Urol Oncol 25:505-9. 2007..The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed... - Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed interventionLaurence Klotz
University of Toronto, Canada
Nat Clin Pract Urol 5:2-3. 2008 - Active surveillance versus radical treatment for favorable-risk localized prostate cancerLaurence Klotz
Sunnybrook Health Sciences Center, University of Toronto, 2975 Bayview Avenue, MG408, Toronto, Ontario M4N 3M5, Canada
Curr Treat Options Oncol 7:355-62. 2006.... - Active surveillance for favorable-risk prostate cancer: who, how and why?Laurence Klotz
University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue MG408, Toronto, ON M4N 3M5, Canada
Nat Clin Pract Oncol 4:692-8. 2007..The results of active surveillance, the criteria for patient selection and the appropriate thresholds for intervention are reviewed in this article... - The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerLaurence Klotz
Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, ON, Canada
BJU Int 102:1531-8. 2008.... - Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?Laurence Klotz
Division of Urology, University of Toronto, and Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
Curr Urol Rep 8:341-4. 2007 - Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancerLaurence Klotz
Department of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, MG408, Toronto, Ontario M4N 3M5 Canada
J Clin Oncol 28:126-31. 2010..Other-cause mortality accounted for almost all of the deaths. Additional studies are warranted to improve the identification of patients who harbor more aggressive disease despite favorable clinical parameters at diagnosis... - Degarelix acetate for the treatment of prostate cancerLaurence Klotz
Division of Urology, University of Toronto, Toronto, Ontario, Canada
Drugs Today (Barc) 45:725-30. 2009..Degarelix is currently available as a 1-month subcutaneous injection and has been approved for the treatment of advanced prostate cancer... - Active surveillance for prostate cancer: a reviewLaurence Klotz
Division of Urology, Professor of Surgery, University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Ontario, Canada
Arch Esp Urol 64:806-14. 2011..In this review article, the rationale, criteria for patient selection, method of follow up, trigger for intervention, and results of active surveillance are reviewed... - Active surveillance for favorable risk prostate cancer: rationale, results, and vis a vis focal therapy roleL Klotz
Sunnybrook Health Sciences Centre Toronto, ON, Canada
Minerva Urol Nefrol 63:145-53. 2011..We propose a complementary role for surveillance and focal therapy... - Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202Laurence Klotz
Sunnybrook Medical Center, Toronto, Ontario, Canada
Eur Urol 58:313. 2010..Based on surveillance studies, about 7% would be upgraded to Gleason 8-10 on rebiopsy [2]. Dutasteride also decreased the rate of urinary retention (1.6% vs 6.7%: a 77.3% relative reduction)... - Active surveillance for prostate cancer: a reviewLaurence Klotz
Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, MG408, Toronto, ON, M4N 3M5, Canada
Curr Urol Rep 11:165-71. 2010..The rationale, patient selection, method of follow-up, triggers for intervention, and recent results of this approach will be reviewed... - MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humansRajiv Chopra
Imaging Research, Sunnybrook Research Institute, 2075 Bayview Ave, Room C713, Toronto, ON, Canada M4N 3M5
Radiology 265:303-13. 2012..To evaluate the feasibility and safety of magnetic resonance (MR) imaging-controlled transurethral ultrasound therapy for prostate cancer in humans... - A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studiesStephane Supiot
Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
Radiother Oncol 88:53-60. 2008..In a phase I trial, we investigated the feasibility of pre-operative radiotherapy for this patient subset... - Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?Scott Bagnall
Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
Semin Oncol 30:587-95. 2003..The outcome of a strategy of selective intervention in good-risk patients based on prostate-specific antigen (PSA) doubling time is summarized... - Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parametersNicholas Bruchovsky
The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
Cancer 107:389-95. 2006..This prospective Phase II study was undertaken to evaluate intermittent androgen suppression as a form of therapy in men with localized prostate cancer who failed after they received external beam irradiation... - Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observationPeter S Bunting
Department of Clinical Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
Clin Biochem 35:471-5. 2002..To determine the intraindividual variation of prostate-specific antigen (PSA) isoforms in prostate cancer patients managed conservatively with watchful observation... - MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studiesKashif Siddiqui
Department of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Urology 76:1506-11. 2010..To confirm the correlation between planning and thermal injury of the prostate as determined by magnetic resonance imaging (MRI) and histology in canine and humans treated with transurethral ultrasound... - Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristicsYonah Krakowsky
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
J Urol 184:131-5. 2010..This is a detailed report of 5 of 453 patients on surveillance who died of prostate cancer... - Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillanceAndrew Loblaw
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
J Urol 184:1942-6. 2010..We determined the proportion of men with nonprogressive prostate cancer on active surveillance who had a trigger for treatment using various measures of prostate specific antigen kinetics... - Intermittent androgen suppression in prostate cancer: the Canadian experienceAntonio Hurtado-Coll
Division of Urology, Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Urology 60:52-6; discussion 56. 2002..Intermittent therapy offers quality-of-life benefits during the off-therapy period, as well as reduced cost of treatment. This article will review the >15 years of Canadian experience with intermittent androgen suppression... - Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinomaRichard Choo
Toronto Sunnybrook Regional Cancer Center, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
BJU Int 94:295-8. 2004..To assess the prostate specific antigen (PSA) doubling time of untreated, clinically localized, low-to-intermediate grade prostate carcinoma... - Variation in patterns of practice in diagnosing screen-detected prostate cancerRobert K Nam
Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Canada
BJU Int 94:1239-44. 2004.... - Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experienceAntonio Hurtado-Coll
Division of Urology, Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Urology 60:45-51; discussion 51. 2002..In this article, we will review the Canadian experience, from the laboratory to the clinic... - Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progressionRichard Choo
Toronto-Sunnybrook Regional Cancer Center and Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
J Urol 167:1664-9. 2002.... - Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic casesNeil Fleshner
Department of Urology (Surgery, Toronto Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
Urology 60:93-7. 2002..The marginal utility of the saturation biopsy is low. Although rare additional cases will be detected using this technique, 18-core peripheral sampling is recommended for these difficult diagnostic cases... - Modeling prostate specific antigen kinetics in patients on active surveillanceLiying Zhang
Division of Clinical Trials and Epidemiology, and Department of Radiation Oncology, and Division of Urology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
J Urol 176:1392-7; discussion 1397-8. 2006..3 years after initiated surveillance... - Active surveillance with selective delayed intervention for favorable risk prostate cancerLaurence Klotz
Division of Urology, University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
Urol Oncol 24:46-50. 2006.... - Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat dietMin Hou
Division of Urology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada
Biochem Biophys Res Commun 397:537-42. 2010..These effects may explain its translational role relating to its anti-neoplastic potential... - Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillanceRoss J Mason
Department of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Eur Urol 59:863-7. 2011..Among renal masses undergoing AS, some grow rapidly and require treatment or progress to metastatic disease. Patient and tumour characteristics related to this more aggressive behaviour have been poorly studied... - The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancerMartin Gleave
Department of Urology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada
Urol Oncol 27:81-6. 2009..To summarize the debate regarding use of intermittent androgen suppression therapy in the treatment of prostate cancer originally presented at the 2007 Spring Meeting of the Society of Urologic Oncology... - Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort studyDavid Margel
Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
J Urol 187:1247-52. 2012..We report magnetic resonance imaging findings among unselected men with low risk prostate cancer before active surveillance... - What can surrogate tissues tell us about the oxidative stress status of the prostate? A hypothesis-generating in-vivo studyKaitlyn F Whelan
Department of Surgery, McMaster University, Hamilton, Ontario, Canada
PLoS ONE 5:e15880. 2010..We sought to determine if the individual's prostatic OS status can be determined by examining the OS in surrogate androgen regulated tissues from the same host... - Expectant management with selective delayed intervention for favorable risk prostate cancerLaurence Klotz
University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5, Canada
Urol Oncol 7:175-9. 2002..In these patients, a policy of close monitoring with selective intervention for the 15-20% who progress rapidly is appealing. This approach is currently the focus of several clinical trials... - Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?Richard Choo
Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
Int J Radiat Oncol Biol Phys 52:674-80. 2002..To evaluate the efficacy of postoperative adjuvant radiotherapy (RT) for positive resection margin and/or pathologic T3 (pT3) adenocarcinoma of the prostate with undetectable postoperative prostate-specific antigen (PSA) levels... - Gonadotropin-releasing hormone: an update review of the antagonists versus agonistsHein Van Poppel
Department of Urology, University Hospitals Leuven, Belgium Division of Urology, University of Toronto, Toronto, Ontario, Canada
Int J Urol 19:594-601. 2012.... - Active surveillance for prostate cancer: for whom?Laurence Klotz
University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5 Canada
J Clin Oncol 23:8165-9. 2005.... - Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancerLaurence Klotz
Department of Surgery, University of Toronto, Ontario, Canada
J Urol 172:S48-50; discussion S50-1. 2004..Results at 8 years are favorable. Longer followup will be required to confirm the safety of this approach in men with long (greater than 15-year) life expectancy... - Cardiovascular effects of androgen depletion and replacement therapyJehonathan H Pinthus
Division of Urology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
Urology 67:1126-32. 2006 - Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancerLaurence Klotz
Division of Urology, Sunnybrook and Women s College, Health Sciences Centre, Toronto, ON, Canada
Clin Prostate Cancer 2:106-10. 2003.... - Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cellsAhmed Q Haddad
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Nutr Cancer 62:668-81. 2010..Other functional categories altered included chromosome organization, apoptosis, and stress response. These results demonstrate the multiple mechanisms of antitumor activity of DHC and fisetin in prostate cancer cells in vitro... - Dietary fat and prostate cancerNeil Fleshner
Division of Urology and Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Canada
J Urol 171:S19-24. 2004..We provide a critical appraisal of the existing evidence for an association between dietary fat consumption and prostate cancer, and review the biologically plausible relationships... - Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumorsRyan Groll
Department of Surgery (Urology, Toronto Sunnybrook Regional Cancer Centre and University of Toronto, Toronto, Ontario, Canada
Urology 59:551-4. 2002..These data call into question whether pathologists should issue a primary score among patients with Gleason 7 cancers at needle biopsy... - Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancerLaurence Klotz
Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario, Canada M4N 3M5
Eur Urol 47:16-21. 2005.... - Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedbackRajiv Chopra
Imaging Research, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
Phys Med Biol 54:2615-33. 2009..This study demonstrates the benefit of adaptive energy delivery using active MR temperature feedback, and an excellent capability to treat precise regions within the prostate gland with this technology... - Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancerLaurence Klotz
Division of Urology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Canada
Nat Clin Pract Urol 2:136-42; quiz 1 p following 149. 2005..The results at 8 years were favorable. Longer follow-up will be required if the study is to confirm the safety of this approach in men with a long life expectancy (> 15 years)... - Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic menDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, 61 Queen St. East, Toronto, Ontario, Canada M5C 2T2
J Urol 169:507-11. 2003..CONCLUSIONS: At levels of soy intake which reduce low-density lipoprotein cholesterol any potential benefits of soy consumption on prostate cancer are likely to occur for reasons other than alterations in hormone activity... - PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practiceLaurence Klotz
Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ont
Can Urol Assoc J 1:17-21. 2007..The consensus conference, which forms the basis for this report, attempted to develop an expert opinion, based on these studies, as to the optimal use of 5ARIs in patient management... - Gleason grading controversies: what the chemoprevention trials have taught usLaurence Klotz
Professor, Department of Surgery, University of Toronto, Toronto, ON
Can Urol Assoc J 3:S115-20. 2009..Re-evaluation of the results based on the pathology of the RP specimens and longer follow-up showed a 30% reduction in cancer incidence with finasteride and no significant differences in Gleason scores compared with placebo... - Feasibility and safety of silicone rubber contrast-enhanced microcomputed tomography in evaluating the angioarchitecture of prostatectomy specimensAlex K Yeung
Department of Medical Imaging, Toronto General Hospital, Toronto, Ontario, Canada
Transl Oncol 4:173-7. 2011..The use of microCT on Microfil-injected prostates seems to be a feasible and specimen-preserving method for visualizing the three-dimensional vessel patterns present in resected human prostates... - Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2Kalathil Suresh
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
Int J Oncol 39:907-13. 2011..HER2 DC induced CTL lysed HER2+ HLA-A2+ tumor cells (MCF-7); significantly reduced lysis occurred in HER2+ HLA-A2- tumor cells (SKOV-3), and the NK cell sensitive cell line K-562... - Analytical accuracy and reliability of commonly used nutritional supplements in prostate diseaseAndrew H Feifer
Department of Surgery, Division of Urology, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
J Urol 168:150-4; discussion 154. 2002..Saw palmetto demonstrated tremendous variability with some samples containing virtually no active ingredients. In contrast, the more regulated substances we measured, such as vitamins and minerals, demonstrated less variation... - Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi
Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
J Urol 180:565-70; discussion 570. 2008..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy... - Combined androgen blockade: the case for bicalutamideLaurence Klotz
Sunnybrook and Women s College Health Sciences Centre University of Toronto, Canada
Clin Prostate Cancer 3:215-9. 2005..An analysis combining historic trial data suggests that bicalutamide 50 mg in addition to androgen deprivation may reduce the hazard ratio (HR) for prostate cancer mortality by 20% (HR, 0.80; 95% CI, 0.66-0.98)... - Urothelial carcinoma of the prostateJuan Palou
Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain
Urology 69:50-61. 2007..Prospective and multicenter trials are needed to identify the real incidence and the best management of these patients. In invasive disease of the prostate, the only large series were designed to investigate invasive bladder cancer... - Outcomes of treatment vs observation of localized prostate cancer in elderly menMark C Scholz
JAMA 297:1651-2; author reply 1652-3. 2007 - Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancerPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
Urology 60:1-6. 2002 - Critical evaluation of hormonal therapy for carcinoma of the prostateGerald W Chodak
Midwest Prostate and Urology Health Center, Chicago, Illinois 60640, USA
Urology 60:201-8. 2002 - [Reevaluation of MAB therapy and progress of endocrine therapy]Laurence Klotz
Gan To Kagaku Ryoho 32:705-28. 2005 - Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancerNicholas Bruchovsky
The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, University of British Columbia, Canada
Clin Genitourin Cancer 6:46-52. 2008..Observations of quality of life (QOL), morbidity, and mortality were obtained from the results of a prospective phase II study of intermittent androgen suppression for recurrent prostate cancer after radiation therapy... - An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood
M D Anderson Cancer Center, Houston, TX, USA
Lancet 372:145-54. 2008.... - A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaHendrik VAN Poppel
Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
Eur Urol 51:1606-15. 2007.... - Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and TreatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 172:S3-5. 2004